Genentech, Protein Design Settle Patent License Dispute
Under the terms of the settlement, Genentech will pay Protein Design Labs reduced royalty fees for asthma drug Xolair, psoriasis drug Raptiva and Avastin, an experimental colon-cancer drug that is expected to be approved by the U.S. Food and Drug Administration early next year.
The specific terms of the deal were not disclosed.
Genentech said it will pay licensing fees to Protein...
To view the full article, register now.